Logo

American Heart Association

  2
  0


Final ID: Mo1116

Evolution of Tricuspid Regurgitation and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from the PURSUIT-HFpEF Registry

Abstract Body (Do not enter title and authors here): Background: Tricuspid regurgitation (TR) is prevalent in patients with heart failure with preserved ejection fraction (HFpEF). However, due to its high vulnerability to hemodynamic loads, the long-term observation may heighten its prognostic values.

Purpose: To investigate the evolution of TR and its impact on clinical outcomes in patients with HFpEF.

Methods: An analysis was performed from a prospective multicenter observational registry for HFpEF (PURSUIT-HFpEF Registry) conducted in the Osaka region of Japan. A total of 1238 patients hospitalized for acute heart failure (HF) (diagnosed by using Framingham criteria) met the inclusion criteria: an LVEF ≥50% and brain natriuretic peptide level ≥100 pg/ml. After excluding patients who died within 1 year, we included 761 patients (age 82 ± 9 years; men, 45%; atrial fibrillation, 37%) whose echocardiographic data at discharge and 1 year were available.

Results: At discharge, 165 patients (21.7%) had moderate to severe TR, which increased to 185 patients (24.3%) at 1 year. Patients were categorized into 4 groups based on the TR evolution: no or mild TR that remained unchanged (n = 522 [69%]), no or mild TR that worsened to moderate to severe (n = 74 [9.7%]), moderate to severe TR that improved to no or mild (n = 54 [7.1%]), and moderate to severe TR that remained unchanged (n = 111 [15%]). During a subsequent follow-up of 33 months, patients with persistent moderate to severe TR had significantly higher mortality rates than the other groups (25.7% vs. 27.0% vs. 27.8% vs. 44.1%, log-rank p < 0.001). Even after adjusting for age, sex, body mass index, left atrial diameter, and left ventricular filling pressure, persistent moderate to severe TR was independently associated with subsequent mortality (hazard ratio, 2.06, 95% confidence interval 1.42-2.99, p < 0.001)

Conclusions: During a one-year follow-up, changes in the TR severity were not rare in patients with HFpEF. Persistent moderate to severe TR alone was associated with subsequent mortality, highlighting the need to address persistent TR to improve the prognosis.
  • Okada, Masato  ( Sakurabashi Watanabe Advanced Healthcare Hospital , Osaka , Japan )
  • Nakatani, Daisaku  ( OSAKA UNIVERSITY GRADUATE SCHOOL , Suita , Japan )
  • Sotomi, Yohei  ( OSAKA UNIVERSITY GRADUATE SCHOOL , Suita , Japan )
  • Sakata, Yasushi  ( OSAKA UNIVERSITY GRADUATE SCHOOL , Suita , Japan )
  • Tanaka, Nobuaki  ( Sakurabashi Watanabe Advanced Healthcare Hospital , Osaka , Japan )
  • Iwakura, Katsuomi  ( Sakurabashi Watanabe Advanced Healthcare Hospital , Osaka , Japan )
  • Seo, Masahiro  ( Osaka General Medical Center , Osaka City , Japan )
  • Hayashi, Takaharu  ( Osaka Police Hospital , Osaka , Japan )
  • Yano, Masamichi  ( Osaka Rosai Hospital , Sakai , Japan )
  • Yamada, Takahisa  ( OSAKA GENERAL MEDICAL CENTER , Osaka , Japan )
  • Yoshio, Yasumura  ( Amagasaki Chuo Hospital , Amagasaki , Japan )
  • Hikoso, Shungo  ( Nara Medical University , Kashihara , Japan )
  • Author Disclosures:
    Masato Okada: DO NOT have relevant financial relationships | Daisaku Nakatani: No Answer | Yohei Sotomi: No Answer | Yasushi Sakata: No Answer | Nobuaki Tanaka: DO NOT have relevant financial relationships | Katsuomi Iwakura: DO NOT have relevant financial relationships | Masahiro Seo: DO NOT have relevant financial relationships | Takaharu Hayashi: No Answer | Masamichi Yano: No Answer | Takahisa Yamada: DO NOT have relevant financial relationships | Yasumura Yoshio: No Answer | Shungo Hikoso: DO have relevant financial relationships ; Speaker:AstraZeneca:Active (exists now) ; Speaker:Phizer:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:Nihon Medi-Physics:Active (exists now) ; Speaker:Nippon Boehringer Ingelheim:Active (exists now) ; Speaker:Nippon Shinyaku:Active (exists now) ; Speaker:TOA EIYO:Active (exists now) ; Speaker:DAIICHI SANKYO COMPANY:Active (exists now) ; Speaker:Sanofi:Active (exists now) ; Speaker:Kowa:Active (exists now) ; Speaker:Kyowa Kirin:Active (exists now) ; Speaker:Otsuka Pharmaceutical:Active (exists now) ; Speaker:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

HFPEF Potpourri: Latest Advances and Emerging Topics

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
3-Mercaptopyruvate Sulfurtransferase is a Critical Regulator of Branched-Chain Amino Acid Catabolism in Cardiometabolic HFpEF

Li Zhen, Doiron Jake, Xia Huijing, Lapenna Kyle, Sharp Thomas, Yu Xiaoman, Nagahara Noriyuki, Goodchild Traci, Lefer David

Age-Related Impairment of Mitochondrial Protein Turnover Exacerbates Pathogenesis of Heart Failure with Preserved Ejection Fraction in Old Mice

Kobak Kamil, Zarzycka Weronika, King Catherine, Borowik Agnieszka, Peelor Frederick, Kinter Michael, Miller Benjamin, Chiao Ying Ann

More abstracts from these authors:
Estimated Plasma Volume Status Reflected Changes In Hemodynamic Parameters On Echocardiogram After Treatment In Patients With Heart Failure With Preserved Ejection Fraction.

Iwakura Katsuomi, Hikoso Shungo, Okada Katsuki, Nakatani Daisaku, Sotomi Yohei, Sakata Yasushi, Tanaka Nobuaki, Okada Masato, Okamura Atsunori, Heitaro Watanabe, Seo Masahiro, Hayashi Takaharu, Yamada Takahisa, Yoshio Yasumura

A Novel Echocardiography Risk Score Predicted Mortality In Patients With Heart Failure With Preserved Ejection Fraction.

Iwakura Katsuomi, Yoshio Yasumura, Hikoso Shungo, Okada Katsuki, Nakatani Daisaku, Sotomi Yohei, Sakata Yasushi, Tanaka Nobuaki, Okada Masato, Okamura Atsunori, Heitaro Watanabe, Seo Masahiro, Hayashi Takaharu, Yano Masamichi, Yamada Takahisa

You have to be authorized to contact abstract author. Please, Login
Not Available